MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer

A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients

Not Applicable
Conditions
Kidney Diseases, Chronic
Thyroid Disease
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2017-06-19
Last Posted Date
2021-06-14
Lead Sponsor
University of California, Irvine
Target Recruit Count
96
Registration Number
NCT03191188
Locations
🇺🇸

University Dialysis Center of Orange, Orange, California, United States

Wound Complications in Head and Neck Surgery

Completed
Conditions
Hypothyroidism; Surgery
Head and Neck Cancer
Wound Heal
Laryngeal Cancer
Laryngeal Fistula
Interventions
First Posted Date
2017-05-01
Last Posted Date
2020-06-01
Lead Sponsor
University of Michigan
Target Recruit Count
51
Registration Number
NCT03134976
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

Not Applicable
Completed
Conditions
Thyroid
Pregnancy Related
Interventions
First Posted Date
2017-04-14
Last Posted Date
2018-03-29
Lead Sponsor
Medstar Health Research Institute
Target Recruit Count
60
Registration Number
NCT03115515
Locations
🇺🇸

Medstar Washington Hospital Center, Washington, District of Columbia, United States

Recurrent Pregnancy Loss and Thyroid Disease

Early Phase 1
Conditions
Recurrent Pregnancy Loss
Interventions
First Posted Date
2017-04-11
Last Posted Date
2017-04-12
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
300
Registration Number
NCT03106935
Locations
🇨🇳

Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics

Early Phase 1
Completed
Conditions
Hypothyroidism Primary
Interventions
First Posted Date
2017-04-05
Last Posted Date
2017-04-06
Lead Sponsor
Georgetown University
Target Recruit Count
41
Registration Number
NCT03102177

Effects of Liothyronine on Energy Expenditure and Cardiovascular Function

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2017-03-31
Last Posted Date
2021-03-26
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
22
Registration Number
NCT03098433
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients

Not Applicable
Completed
Conditions
Hypothyroidism
Interventions
Other: a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)
First Posted Date
2017-03-30
Last Posted Date
2017-03-30
Lead Sponsor
Azienda USL Modena
Target Recruit Count
80
Registration Number
NCT03095963

Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)

Phase 4
Conditions
Subclinical Hypothyroidism
Heart Failure
Interventions
First Posted Date
2017-03-30
Last Posted Date
2018-03-29
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
124
Registration Number
NCT03096613
Locations
🇨🇳

Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing, Beijing, China

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

Phase 4
Completed
Conditions
Hypothyroidism;Postablative
Interventions
First Posted Date
2017-03-29
Last Posted Date
2022-04-05
Lead Sponsor
IBSA Institut Biochimique SA
Target Recruit Count
66
Registration Number
NCT03094416
Locations
🇺🇸

California Head and Neck Specialists, La Jolla, California, United States

🇺🇸

Coastal Metabolic Research Centre, Ventura, California, United States

🇺🇸

Washington Hospital Center, Washington, District of Columbia, United States

and more 6 locations

Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients

Phase 2
Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2017-02-14
Last Posted Date
2023-04-21
Lead Sponsor
Azienda USL Modena
Target Recruit Count
160
Registration Number
NCT03053115
Locations
🇮🇹

AziendaUSLModena, Modena, Italy

© Copyright 2025. All Rights Reserved by MedPath